

1 **Direct capsid labeling of infectious HIV-1 by genetic code expansion allows**
2 **detection of largely complete nuclear capsids and suggests nuclear entry of**
3 **HIV-1 complexes via common routes**

4

5

6 Sandra Schifferdecker¹, Vojtech Zila¹, Thorsten G. Müller¹, Volkan Sakin¹, Maria
7 Anders-Össwein¹, Vibor Laketa^{1,2}, Hans-Georg Kräusslich^{1,2}, Barbara Müller^{1*}

8

9 ¹ Department of Infectious Diseases, Virology, University Hospital Heidelberg,
10 Heidelberg, Germany

11 ² German Center for Infection Research, partner site Heidelberg, Germany

12

13 *To whom correspondence should be addressed: [Barbara.mueller@med.uni-](mailto:Barbara.mueller@med.uni-heidelberg.de)
14 [heidelberg.de](mailto:Barbara.mueller@med.uni-heidelberg.de)

15

16

17

18 **Keywords:** HIV-1, capsid, click labeling, amber suppression, genetic code
19 expansion, primary CD4⁺ T cells, electron microscopy, correlative microscopy, STED,
20 super-resolution microscopy

21 **Abstract**

22 The cone-shaped mature HIV-1 capsid is the main orchestrator of early viral
23 replication. After cytosolic entry, it transports the viral replication complex along
24 microtubules towards the nucleus. Capsid uncoating from the viral genome apparently
25 occurs beyond the nuclear pore. Observation of post-entry events *via* microscopic
26 detection of HIV-1 capsid protein (CA) is challenging, since epitope shielding limits
27 immunodetection, and the genetic fragility of CA hampers other labeling
28 approaches. Here, we present a minimally invasive strategy based on genetic code
29 expansion and click chemistry that allows for site-directed fluorescent labeling of HIV-
30 1 CA, while retaining virus morphology and infectivity. Thereby, we could directly
31 visualize virions and subviral complexes using advanced microscopy, including
32 nanoscopy and correlative imaging. Quantification of signal intensities of subviral
33 complexes showed that the amount of CA associated with nuclear complexes in HeLa-
34 derived cells and primary T cells is consistent with a complete capsid and revealed that
35 treatment with the small molecule inhibitor PF74 did not result in capsid dissociation
36 from nuclear complexes. Cone-shaped objects detected in the nucleus by electron
37 tomography were clearly identified as capsid-derived structures by correlative
38 microscopy. High-resolution imaging revealed dose-dependent clustering of nuclear
39 capsids, suggesting that incoming particles may follow common entry routes.

40

41 **Introduction**

42 The cone-shaped capsid that encases the viral RNA genome and replication proteins
43 is a characteristic feature of infectious human immunodeficiency virus type 1 (HIV-1)
44 particles. Data obtained by many research groups over the past decade have revised
45 our understanding of the role of the mature capsid in HIV-1 replication, placing this
46 structure at the center stage of post-entry replication steps (reviewed in e.g., (Aiken
47 and Rousso, 2021; Engelman, 2021; Guedan et al., 2021; James, 2019; Novikova et
48 al., 2019). Upon fusion of the virion envelope with the cell membrane, the capsid, which
49 consists of ~1,200-1,500 monomers of the capsid protein CA (Briggs et al., 2003), is
50 released into the cytosol. It then usurps host cell factors to traffic towards the nucleus.
51 Reverse transcription of the viral RNA into dsDNA is initiated during passage of the
52 subviral structure through the cytosol. Following import into the nucleus, the viral
53 dsDNA is covalently integrated into the host cell genome by the viral integrase. Prior
54 to integration, the surrounding capsid shell needs to expose the dsDNA in a process
55 termed uncoating. However, the precise mechanisms, location, and timing of capsid
56 uncoating are still under investigation.

57 Initially, the HIV-1 capsid was presumed to rapidly dissociate upon cell entry, based
58 on little or no CA detected associated with isolated post-entry complexes (reviewed in
59 (Campbell and Hope, 2015)). Rapid or gradual disassembly in the cytosol was also
60 supported by several studies that applied fluorescence imaging to analyze subviral
61 complexes in infected cells (e.g., (Hulme et al., 2011; Mamede et al., 2017; Xu et al.,
62 2013). However, the finding that CA or the capsid lattice, directly interacts with various
63 host factors involved in post-entry replication steps (cytosolic proteins, including
64 proteins involved in microtubular transport, but also nucleoporins and even the nuclear
65 protein CPSF6; reviewed in (Engelman, 2021; Naghavi, 2021; Saito and Yamashita,
66 2021)) implied involvement of at least a partial lattice structure in later stages of post-
67 entry replication. Furthermore, increasing evidence from imaging-based analyses
68 argued for capsid uncoating at the nuclear pore (Burdick et al., 2017; Francis et al.,
69 2020a; Francis et al., 2016; Francis and Melikyan, 2018), or even indicated passage
70 of (nearly) intact capsids through nuclear pores (Burdick et al., 2020; Li et al., 2021;
71 Muller et al., 2021; Zila et al., 2021). The recent detection of cone-shaped objects in
72 the nuclear pore channel and inside the nucleus by correlative light and electron
73 microscopy (CLEM) (Zila et al., 2021), and intranuclear separation of CA or IN from

74 reverse transcribed dsDNA (Muller et al., 2021) also support the model that the nucleus
75 is the site of HIV-1 uncoating.

76 One explanation for apparent discrepancies between different studies are the methods
77 that have been used for CA detection in fluorescence microscopy. Since the
78 modification of CA by genetic labeling strategies proved to be challenging, most studies
79 applied immunofluorescence (IF) staining or indirect labeling through a capsid binding
80 protein (e.g. (Burdick et al., 2017; Francis et al., 2016; Hulme et al., 2015; Mamede et
81 al., 2017; Peng et al., 2014; Zila et al., 2019). A limitation of IF is that staining efficiency
82 may vary substantially depending on the antibody and detection conditions used, as
83 well as on differential exposure or shielding of epitopes due to conformational changes
84 or different intracellular environments. We could indeed show previously that
85 immunostaining efficiency of CA in the nucleus of host cells strongly depends on cell
86 type and experimental conditions (Muller et al., 2021). Furthermore, IF is incompatible
87 with live cell analyses. Infectious HIV-1 derivatives carrying fluorescent CA would
88 resolve these limitations and allow the direct observation of entering capsids with
89 quantitative analyses.

90 Direct genetic labeling of viral capsid proteins is challenging, however. Capsid proteins
91 are generally small proteins that need to assemble into ordered multimeric lattices. The
92 resulting assemblies must be stable during virus formation and transmission to a new
93 target cell, but also ready to disassemble in the newly infected cell, requiring structural
94 flexibility of the protomers. Beyond protein-protein interactions involved in capsid
95 assembly itself, capsid proteins generally undergo crucial interactions with other
96 components of the virion, e.g., the viral genome. Finally, the capsid surface represents
97 an essential contact interface between virus and host cell in the early phase of
98 infection, mediating cell entry in the case of non-enveloped viruses, or interacting with
99 critical host cell dependency or restriction factors in the case of enveloped viruses.
100 Consequently, a large proportion of the surface exposed amino acids of a viral capsid
101 protein is involved in intermolecular contacts that are crucial for virus replication, which
102 renders these proteins highly susceptible to genetic modification. Fusion of a capsid
103 protein to a relatively large genetic label, e.g., green fluorescent protein (GFP) or other
104 fluorescent proteins, is thus generally prone to severely affect virus infectivity.

105 These considerations also apply to HIV-1 CA. The protein is encoded as a subdomain
106 of the structural polyprotein Gag, from which it is released by the viral protease (PR)
107 concomitant with virus budding to allow for formation of the mature capsid. With a

108 molecular mass of ~24 kDa, mature CA is of a similar size as GFP. Hexa- and
109 pentamers of CA are the core structural elements of the immature Gag polyprotein
110 shell forming the nascent virus bud in HIV-1 producing cells, as well as of the mature
111 capsid lattice. CA pentamers, immature and mature hexamers employ different
112 protein-protein interfaces; together, these interfaces involve most of the exposed
113 surface of the CA monomer (reviewed in (Mattei et al., 2016)). Accordingly, scanning
114 mutagenesis analyses found HIV-1 CA to be highly genetically fragile (Rihn et al.,
115 2013; von Schwedler et al., 2003), with up to 89% of single amino acid exchanges
116 tested abolishing or severely affecting virus replication (Rihn et al., 2013). It is thus not
117 surprising that the introduction of genetically encoded labels - GFP or even a small
118 peptide tag - at various positions within HIV-1 CA have resulted in loss or severe
119 reduction of infectivity. Complementation with wild-type (wt) virus, from at least
120 equimolar amounts of wt CA to a substantial molar excess, was essential to restore
121 virus infectivity (Burdick et al., 2020; Campbell et al., 2008; Pereira et al., 2011; Zurnic
122 Bonisch et al., 2020). While the use of wt complemented particles can be sufficient for
123 fluorescent labeling, it is unclear whether the modified CA molecules are an integral
124 part of the mature CA lattice; only ~ 50% of CA molecules present inside the virion are
125 eventually used to form the mature capsid (Briggs et al., 2004; Lanman et al., 2004),
126 and incorporated fusion proteins may be preferentially excluded or less stably
127 integrated into the mature lattice.

128 We therefore established and applied a minimal invasive labeling strategy for HIV-1
129 CA based on genetic code expansion and click labeling. This method involves the
130 exchange of a selected amino acid residue in the protein of interest with a non-
131 canonical amino acid (ncAA) carrying a highly reactive bio-orthogonal functional group
132 by a process termed amber suppression (Figure 1a); this residue is subsequently
133 covalently coupled to a fluorophore functionalized with a cognate reaction partner
134 (Figure 1a; reviewed in e.g. (Lang and Chin, 2014; Muller et al., 2019; Nikic and Lemke,
135 2015)). Using this approach, we generated a CA-labeled HIV-1 derivative that largely
136 retained infectivity; in contrast to previous approaches for direct CA labeling, our
137 minimally modified derivative did not require complementation with wt virus. Direct
138 labeling with a bright and photostable chemical dye allows the application of various
139 imaging methods, i.e., live-cell imaging, super-resolution nanoscopy, or CLEM. The
140 virus variant click labeled with a bright and photostable chemical dye thus enabled us
141 to directly assess the amount of CA associated with entering subviral complexes

142 outside and within the nucleus of infected HeLa-derived cells and primary CD4⁺ T-
143 cells, to visualize CA containing structures in the nucleus by nanoscopy and correlative
144 microscopy and to study the effect of the CA-binding drug PF74 on the nuclear
145 complexes.

146

147 **Results**

148 *Generation of an HIV-1 variant carrying a bio-orthogonal amino acid within CA*

149 To allow for minimally invasive labeling of HIV-1 CA by genetic code expansion (GCE;
150 Figure 1a), we introduced an amber stop codon at a position of interest into the CA
151 coding sequence within the *gag* open reading frame of the proviral plasmid pNLC4-3
152 (Bohne and Krausslich, 2004). In order to avoid GCE modification of the viral protein
153 R (Vpr), which is incorporated into the virion in high amounts (Muller et al., 2000), we
154 first exchanged the amber stop codon of *vpr* to an opal codon (TGA), resulting in
155 plasmid pNLC4-3*. Albeit this mutation did not alter the coding sequence of viral
156 proteins or virion infectivity, the corresponding virus was termed HIV-1* to indicate this
157 modification. Since neither the efficiency of amber suppression in a given sequence
158 context in eukaryotic cells, nor the effect of ncAA incorporation on viral functionality
159 can be predicted with certainty, we tested a panel of 18 amber mutations at sites
160 located towards the outer surface of the capsid lattice for suppression efficiency and
161 virus infectivity (Schifferdecker, Sakin et al., in preparation). Based on a comparison of
162 Gag expression levels and viral infectivity upon ncAA incorporation, we selected a virus
163 variant in which residue alanine 14 in CA was replaced by a non-canonical amino acid
164 (HIV-1*CA14^{ncAA}) for further analyses.

165 For virus preparation, HEK293T cells were co-transfected with the respective mutant
166 proviral plasmid and pNESPylRS-eRF1dn-tRNA. The latter plasmid encodes for a
167 complete amber suppression system, consisting of modified tRNA, a cognate
168 genetically engineered pyrrolysine aminoacyl-tRNA synthetase (Nikic et al., 2016), and
169 a dominant-negative version of the eukaryotic release factor eRF1 that improves
170 amber suppression efficiency in eukaryotic cells (Schmied et al., 2014). To produce
171 functionalized virus particles, cells were grown in the presence of the small ncAA
172 cyclopropene lysine (CpK). While truncation of Gag at position 14 of CA would prevent
173 virus formation, incorporation of CpK by amber suppression should result in the
174 expression of full-length Gag and thereby promote HIV-1 particle assembly.


175 Immunoblot analysis of cell lysates indeed demonstrated the presence of full-length
176 Gag polyprotein precursor when HIV-1*CA14^{TAG} expressing cells were grown in the
177 presence of CpK, whereas full-length Gag was not detected when CpK was omitted
178 from the growth medium (Figure S1). Thin-section electron microscopy (EM) revealed
179 late budding sites and immature- as well as mature-like virions at the plasma
180 membrane and in the vicinity of HIV-1*CA14^{ncAA} expressing cells, that were
181 morphologically indistinguishable from typical HIV-1 wild-type (wt) budding sites and
182 virions (Figure 1b). We concluded that Gag expression of HIV-1*CA14^{TAG} is ncAA
183 dependent and the modified CA domain is competent for immature and mature lattice
184 assembly.

185

186 *Characterization of click labeled HIV-1 virions*

187 We next prepared virus particles from the supernatant of HIV-1*CA14^{ncAA} producing
188 cells and subjected them to click labeling using the membrane-permeable dye silicon
189 rhodamine tetrazine (SiR-Tet; (Lukinavicius et al., 2013)), generating HIV-1*CA14^{SiR}.
190 As a control, HIV-1* wt particles were prepared under amber suppression conditions
191 and stained in parallel. Consistent with the detection of viral assembly sites and
192 particles in electron micrographs (Figure 1b), virus was recovered from the tissue
193 culture supernatant of HIV-1*CA14^{ncAA} expressing cells. Particle yields were somewhat
194 reduced compared to the HIV-1* wt control, in line with the fact that amber suppression
195 is usually incomplete in eukaryotic cells (optimal ncAA incorporation efficiencies in the
196 range of ~25-50 %; e.g., (Sakin et al., 2017; Schmied et al., 2014). On average, we
197 obtained 5-10-fold lower yields for HIV-1*CA14^{SiR} compared to HIV-1* (Figure 1c, d).
198 Consistent with the observation of morphologically mature particles by EM, click
199 labeled particles displayed regular Gag and GagPol processing products (Figure 1e),
200 with clear bands for mature RT heterodimer (p51, p66) and mature CA (p24). In-gel
201 fluorescence revealed a distinct SiR labeled band corresponding to a mass of
202 approximately 24 kDa for HIV-1*CA14^{SiR}, but not for HIV-1* control particles (Figure
203 1f). Taken together, these findings indicate specific GCE-dependent labeling of CA *via*
204 amber suppression at position 14 of HIV-1 CA.

205



206

207 **Figure 1. Production and characterization of click labeled HIV-1 (HIV-1*CA14^{SiR}).** (a)
 208 Experimental scheme for GCE and click-labeling. The system used here requires the
 209 introduction of an amber stop codon (UAG) at a specific site into the coding sequence of the
 210 protein of interest. A genetically engineered bio-orthogonal tRNA / aminoacyl-tRNA synthetase
 211 pair mediates incorporation of a non-canonical amino acid (ncAA) at the chosen position. In a
 212 second step, a highly reactive group of the ncAA is covalently linked to a fluorophore carrying
 213 a cognate reactive group (e.g., a tetrazine group reacting with a cyclopropane group at the
 214 ncAA via strain-promoted inverse electron-demand Diels-Alder cycloaddition (SPIEDAC)).
 215 Image created with BioRender.com (b) Morphology of HIV-1*CA14^{ncAA} assembly sites and
 216 particles. HEK293T cells were co-transfected with pNLC4-3*CA14^{TAG} and pNESPyIRS-
 217 eRF1dn-tRNA and grown in the presence of 500 μ M CpK. At 44 h p.t., cells were fixed,
 218 embedded, and analyzed by thin-section EM as described in materials and methods. (c,d)
 219 Virus production. Click labeled particles were prepared from the supernatant of HEK293T cells
 220 co-transfected with either pNLC4-3* or pNLC4-3*CA14^{TAG} and pNESPyIRS-eRF1dn-tRNA.
 221 Cells were grown in the presence of 500 μ M CpK as described in materials and methods.
 222 Particle yield in the final preparations was determined via quantitation of RT activity (SG-PERT
 223 assay; (Pizzato et al., 2009)) (c) and by determination of CA amounts using quantitative
 224 immunoblot as described in materials and methods (d). The graphs show mean values and

225 *SD from four independent experiments. (e) Immunoblot analysis of virus preparations. Particle*
226 *lysates were separated by SDS-PAGE, and proteins were transferred to nitrocellulose*
227 *membranes by semi-dry blotting. Viral proteins were detected using polyclonal antisera raised*
228 *against recombinant HIV-1 RT or CA. Bound antibodies were detected by quantitative*
229 *immunofluorescence with a Li-COR CLx infrared scanner, using secondary antibodies and*
230 *protocols according to the manufacturer's instructions. An asterisk indicates non-specific*
231 *reactivity with bovine serum albumin carried over from the medium (f) In-gel fluorescence.*
232 *Particle lysates prepared as in (e) were separated by SDS-PAGE, and the acrylamide gel was*
233 *scanned using a Li-COR CLx infrared scanner set at an emission wavelength of 700 nm.*


234

235 *Fluorescence labeling and infectivity of click labeled virions*

236 To test specificity and efficiency of SiR staining, labeled particles adhered to a glass
237 chamber slide were fixed, permeabilized, and immunostained with antiserum raised
238 against HIV-1 CA to validate that detected signals corresponded to virus particles.
239 Confocal micrographs were recorded in the channels corresponding to the CA
240 immunofluorescence (IF) stain (green) and direct CA labeling with SiR (magenta)
241 (Figure 2a). Regions of interest (ROIs) corresponding to the position of virus particles
242 were defined based on CA(IF) signals. Measurement of SiR fluorescence intensities in
243 these ROIs revealed weak background staining in the case of HIV-1* (Figure 2a, left
244 panel). In contrast, distinct SiR signals co-localizing with CA(IF) punctae were detected
245 for HIV-1*CA14^{SiR} (Figure 2a, right panel). Quantitative analyses of images from
246 multiple independent experiments confirmed this visual impression (Figure 2b). Only
247 ~8.5% of HIV-1* particles were classified as SiR positive, with fluorescence intensities
248 only slightly above the background level (~1,000 a.u.). In contrast, >95% HIV-
249 1*CA14^{SiR} particles displayed clear SiR staining, with a mean fluorescence intensity of
250 ~15,000 a.u. Variation in SiR fluorescence intensities between individual particles is
251 expected, since particle size and CA content of HIV-1 virions varies, with ~1,700-3,100
252 CA monomers estimated per particle (Carlson et al., 2008)). Beyond that, the range of
253 SiR signal intensities observed also indicates a range of click labeling efficiencies.
254 Despite some variability in the preparation, the vast majority of HIV-1*CA14^{CpK} particles
255 could be efficiently click labeled with SiR, attaining fluorescence intensities suitable for
256 fluorescence microscopy of infected cells.

257 To test the effect of introducing a synthetic fluorophore at position 14 on CA
258 functionality, the infectivity of click labeled particles was assessed by titration of labeled

259 particles on TZM-bl cells, followed by immunostaining against the HIV-1 matrix protein
260 (MA) to identify infected cells. As shown in Figures 2c and d, relative infectivity of HIV-
261 1*CA14^{SiR} was only mildly reduced by an average of ~2-fold compared to HIV-1*, a
262 substantial improvement compared to previous genetically labeled derivatives in the
263 absence of complementation (Burdick et al., 2020; Campbell et al., 2008; Pereira et
264 al., 2011; Zurnic Bonisch et al., 2020). Thus, minimal invasive labeling by GCE allows
265 direct labeling of HIV-1 CA without requiring complementation with wt virus.
266



267

268 **Figure 2. Characterization of CA click labeled particles. (a) Analysis of labeling efficiency.**
269 *Particles harvested from the supernatant of virus producing HEK239T cells were subjected to*
270 *click labeling. Particles were then immobilized on PEI coated chamber slides, fixed, and*
271 *permeabilized. Particles were immunostained using antiserum raised against HIV-1 CA, and*
272 *specimens were imaged by spinning disk confocal microscopy (SDCM). Scale bars 5 μ m. (b)*
273 *Hexabin plots of detected particles. Mean intensities of CA(SiR) are plotted against mean*
274 *intensity CA(IF) for HIV-1* and HIV-1*CA14^{SiR}. The color intensity of the hexagons*
275 *corresponds to the number of particles displaying the indicated intensity values. The graphs*
276 *represent pooled data from 12 fields of view from three independent virus preparations. The*
277 *red line indicates the threshold $t=1,000$. (c) Infectivity of click labeled particles. The indicated*
278 *virus particles were prepared as in (a) and subjected to click labeling. Particle yield was*

279 assessed by RT activity assay (Pizzato et al., 2009), and samples were titrated on TZM-bl
280 indicator cells seeded in 15-well ibidi μ -slide angiogenesis dishes. 50 μ M T-20 was added at 6
281 h p.i. to prevent second-round infection in the case of wt. Cells were fixed, permeabilized, and
282 immunostained using a polyclonal rabbit antiserum raised against recombinant HIV-1 MA at
283 48 h p.i. Samples were imaged by SDCM. The percentage of infected cells was determined
284 using Fiji software. The graphs show mean values and SD from five independent infection
285 experiments using five independent particle preparations ($n=5,700-7,700$ cells were counted
286 per condition). Lines represent linear regression based on the mean values. **(d)** Relative
287 infectivity of a virus preparation (% infected cells/mU RT) was determined as in (c), and the
288 values obtained for HIV-1*CA14^{SiR} were normalized to the value obtained for HIV-1* virus in
289 the same experiment. All cells counted in (c) were used for quantification. The graph
290 represents the mean value and SD from five independent experiments.

291

292

293 *Detection of click labeled HIV-1 in infected cells*

294 Having established a suitable labeling strategy, we used labeled particles to infect
295 target cells. Initial experiments were performed in the model cell line HeLa TZM-bl.
296 Cells infected with HIV-1*CA14^{SiR} at an MOI~0.8 were fixed at 18 h post infection (h
297 p.i.). Immunostaining with antiserum against CA was performed under conditions that
298 allow for immunodetection of cytosolic and nuclear complexes (Muller et al., 2021) to
299 validate that detected SiR signals corresponded to HIV-1 particles. Labeled particles
300 could be visualized by spinning disc confocal microscopy (SDCM) in the cellular
301 environment (Figure S2). Confocal images revealed punctate SiR signals in the
302 cytosol, close to the nuclear envelope and within the nucleus of infected cells. Co-
303 localization with CA(IF) staining confirmed that these signals represented entering viral
304 structures (Figure 3a and Figure S3).

305 Next, TZM-bl cells infected with HIV-1* or HIV-1*CA14^{SiR} were fixed and analyzed for
306 the presence of click labeled subviral particles inside the nucleus at different time
307 points after infection. Consistent with earlier results (Zurnic 2020, Burdick 2020, Müller
308 2021), we observed nuclear CA(IF) positive foci in HIV-1* infected cells as early as 6
309 h post infection (Figure 3b, black), while such signals were absent in noninfected cells
310 (Figure 3b, grey). Importantly, we detected SiR positive complexes in the nucleus of
311 HIV-1*CA14^{SiR} infected cells, with the vast majority also positive for CA(IF) (Figure 3b,
312 magenta). Nuclear entry appeared to be delayed for HIV-1*CA14^{SiR} compared to HIV-

313 1* by approximately 12 h. Nevertheless, comparable numbers of cells with detectable
314 capsid-like objects in the nucleus and the number of objects per cell were reached
315 between 12 and 18 h p.i. (Figure 3b and c). At 12 h p.i., HIV-1*CA14^{SiR} reached the
316 highest number of nuclear particles per cell, with an average of 4.58 ± 4.12 , similar to
317 HIV-1* with 5.91 ± 4.11 .

318 Delayed detection of subviral complexes in the nucleus may be due to slower uptake,
319 slower trafficking towards the nuclear envelope, delayed passage through the NPC, or
320 a combination thereof. In order to distinguish between these possibilities, we extended
321 the time-resolved quantification to objects in close vicinity to the nuclear envelope
322 (Figure 3d). This analysis revealed that the HIV-1*CA14^{SiR} derived subviral structures
323 reached the nuclear envelope with similar kinetics to HIV-1* particles (Figure 3d, NE
324 assoc.). A comparable average proportion of CA containing objects was detected at
325 the nuclear envelope in both cases at 6 h, while the numbers of nuclear capsids were
326 lower for HIV-1*CA14^{SiR} at that time (Figure 3d, Nucleus). In contrast, the highest
327 proportion of HIV-1*CA14^{SiR} nuclear objects with $4.20 \pm 1.80\%$ was detected at 18 h
328 p.i., while HIV-1* reached similar levels already at 6 h p.i. We conclude that uptake and
329 intracellular trafficking of HIV-1*CA14^{SiR} complexes occurs with similar efficiency as for
330 the wt virus, but transport into the nucleus is slower, offering a possible explanation for
331 the slightly reduced infectivity of HIV-1*CA14^{SiR} virions. This implies that the
332 mechanistic action of the capsid in nuclear import underlies tight margins with respect
333 to its biophysical properties.

334


358 *Characterization of nuclear CA^{SiR} containing complexes*

359 A long-standing question in the field of HIV-1 early replication is the question of when
360 and where capsid uncoating takes place. The possibility to directly detect CA
361 molecules clicked to a synthetic fluorophore enabled us to assess the amounts of CA
362 associated with subviral complexes at different intracellular sites, without the influence
363 of differential epitope accessibility or of a tag domain that potentially confers different
364 properties to a subpopulation of CA molecules. Nevertheless, comparing labeling
365 intensities for nuclear, cytoplasmic, and extracellular particle-associated structures
366 may be confounded in diffraction-limited microscopy by the failure to resolve closely
367 adjacent individual capsids. Clusters of nuclear capsids had indeed been observed by
368 CLEM analyses in our previous study (Muller et al., 2021).

369 To determine whether nuclear cluster formation occurred under our conditions, we
370 exploited the fact that the chemical dye conjugated to the capsid surface renders the
371 modified virus suitable for super-resolution microscopy. With a lateral resolution of <50
372 nm, STED nanoscopy allows visual separation of closely adjacent CA objects. TZM-bl
373 cells were infected with HIV-1*CA14^{SiR} at two different MOIs. An MOI of ~0.8
374 corresponded to the conditions generally used in our experiments; a 10-fold higher
375 virus dose (MOI ~8) was applied in a parallel experiment to potentially enhance capsid
376 clustering. At 18 h p.i., cells were fixed, immunostained against CA, and imaged using
377 a STED system in confocal and STED mode (Figure 4). Nuclear CA(IF)/(SiR) double-
378 positive objects were detected under both conditions (Figure 4a, arrowheads). While
379 these objects appeared as individual punctae in diffraction-limited micrographs from
380 the IF and SiR channels at both MOIs (Figure 4b, top and middle row), imaging of the
381 SiR channel in STED mode revealed differences between individual punctae. Some
382 diffraction-limited punctae in the nucleus represented individual capsid-like objects
383 when imaged by STED (Figure 4b, left panel, bottom row). In contrast, other punctae
384 were resolved into small clusters of 2-4 closely apposed CA-containing objects by
385 super-resolution microscopy (Figure 4b, right, bottom panel), consistent with
386 observations made by electron tomography (Muller et al., 2021; Zila et al., 2021). A
387 quantitative analysis of cluster sizes (Figure 4c) revealed that the propensity for capsid
388 clustering in the nucleus correlated with the amount of virus used for infection: at an
389 MOI~0.8, the vast majority of punctae (~88%) corresponded to individual capsid-like
390 objects in the nucleus, and clusters of more than two objects were not observed. On
391 the other hand, almost half of the nuclear punctae (~43%) corresponded to clusters of

392 2-4 objects when cells were infected with the high MOI~8. We conclude that nuclear
393 capsid clustering is rarely observed at the MOI of 0.8 used throughout this study. The
394 previously observed capsid clustering in distinct nuclear positions appears to occur
395 preferentially at high MOI.

396



397


398 **Figure 4. Dose-dependent clustering of nuclear capsids in HeLa-derived cells.** TZM-bl
399 cells were infected with HIV-1*CA14^{SiR} at the indicated MOI for 18 h, treated with 15 μ M PF74
400 for 1 h, immunostained against CA (green) and lamin A (blue) and imaged using an Abberior
401 STED setup. Mean filter and background subtraction was applied to all images for clarity. **(a)**
402 Micrographs of TZM-bl cells infected with an MOI ~0.8 (left) or MOI ~8 (right). Arrowheads
403 indicate nuclear CA(IF)/CA(SiR) positive objects shown enlarged in (b). Scale bars: 10 μ m. **(b)**
404 Representative images of nuclear CA containing objects from cells infected with a low MOI
405 (MOI~0.8, left panel) or a high MOI (MOI~8, right panel). CA(IF) and CA(SiR) were imaged in
406 confocal mode (top and middle row, respectively). CA(SiR) images were also recorded in
407 STED mode (bottom row). The figure shows four representative foci each from one of two
408 individual experiments. Mean filter and background subtraction were applied. Scale bars: 500
409 nm. **(c)** Diffraction-limited nuclear foci were analyzed by STED nanoscopy in cells infected with

410 *an MOI~0.8 (n = 33) and an MOI~8 (n =44) and classified by the number of individual capsids*
411 *per focus.*

412 We next proceeded to SiR fluorescence intensity measurements, comparing the signal
413 intensity of extranuclear HIV-1 particles to that of subviral structures in the nucleus.
414 Staining of the plasma membrane with mCling before infection revealed that under our
415 conditions most cell-associated particles in the cytosolic region represented virions
416 present in endosomes, corresponding to a pre-fusion state of the virus (Figure S4). To
417 ensure that these extranuclear punctae represented single objects, cytoplasmic foci
418 were analyzed in STED mode. We found that ~95% (n=79) of analyzed objects
419 corresponded to an individual object, while only ~5% (n=4) of these foci were resolved
420 into two objects by nanoscopy (Figure S5). As illustrated by the cartoon in Figure 5a,
421 complete virions comprise on average ~2,400 CA molecules, while only ~1,200-1,500
422 of these are part of the mature fullerene capsid (Briggs 2003, Carlson 2008, Lanman
423 2004) that represents a post-fusion state. Assuming equal click labeling efficiency of
424 CA14^{ncAA} for molecules that are part of the mature lattice and those that remain free in
425 the viral volume, the average SiR intensity of complete capsids would be expected to
426 correspond to ~60% of the average intensity of complete virions from the same
427 preparation. We infected TZM-bl cells at an MOI of 0.8 and quantified the SiR intensity
428 of >6,000 virions attached to the cell or in the cytosolic region and of >100 nuclear
429 punctae. The average SiR intensity of cell-attached and (mostly) endosomal particles
430 in the cytosolic region exhibited an average of 17,649 a.u.. In contrast, the SiR intensity
431 of nuclear subviral structures averaged 9,835 a.u. (Figure 5b), i.e., ~56% of the
432 average intensity of complete virions, in line with the predicted relative CA content of
433 the mature capsid. Based on these findings, we conclude that the CA(SiR) containing
434 objects in the nuclei of these cells correspond approximately to a full complement of
435 the mature capsid.

436

437



438

439 **Figure 5. Largely intact capsids are detected in the nucleus of HeLa-derived cells.** TZM-
440 *bl* cells were infected with HIV-1* or HIV-1*CA14^{SiR} (MOI~0.8), treated with 15 μ M PF74 for 1
441 h before fixation at the indicated time points and imaged by SDCM. (a) Scheme of the relative
442 CA content in complete virions (~ 2,400 CA) on glass/plasma membrane or in endosomes in
443 the cytosol. Post-fusion capsids contain only the CA molecules incorporated into the mature
444 capsid lattice (~ 1,500 CA). Image created with BioRender (b) Quantification of CA(SiR)
445 intensities associated with CA(IF) positive objects at the indicated localizations. Data from
446 three independent experiments are shown. Cells from seven fields of view were analyzed
447 ($n_{particles}$ = 6,441 PM/cytoplasm, 135 nucleus). Lines indicate median values (PM/cytoplasm:
448 $17,649.22 \pm 11,663.47$; nucleus: $9,835.08 \pm 5,708.14$) and interquartile range. Significance
449 was determined by two-tailed Student's *t*-test ($*** < 0.001$). (c) Quantification of CA(SiR)
450 intensities of nuclear objects. TZM-*bl* cells were treated with DMSO or 15 μ M PF74 for 1 h
451 prior fixation at 17 h p.i.. Lines indicate median values (DMSO: $2,086.83 \pm 456.35$, $n=100$;
452 PF74: $2,164.51 \pm 783.45$, $n=100$) and interquartile range. Significance was determined by two-
453 tailed Student's *t*-test (*n.s.* >0.05).

454

455 The small molecule inhibitor PF74 (Blair et al. 2010) binds to the HIV-1 capsid in a
456 pocket overlapping the binding sites for the FG motifs of various nucleoporins and for
457 the nuclear host protein CPSF6; the compound inhibits HIV-1 replication by multiple
458 mechanisms (reviewed in (Thenin-Houssier and Valente, 2016)). Treatment with high
459 concentrations of PF74 has been reported to destabilize the capsid ((Blair et al., 2010;
460 Price et al., 2014; Shi et al., 2011), but data obtained using CA(IF) detection argued
461 against a PF74 induced loss of CA from nuclear complexes (Müller 2021). Since we
462 cannot exclude that results obtained by immunodetection are influenced by differential
463 CA epitope exposure, we re-addressed this issue employing direct CA labeling. TZM-
464 *bl* cells were infected with HIV-1*CA14^{SiR} particles for 17 h and treated with 15 μ M
465 PF74 or DMSO for 1 h, followed by fixation, permeabilization, methanol extraction, and
466 SDCM imaging. As shown in Figure 5c, CPSF6 was removed from the subviral

467 complexes, in accordance with earlier results (Muller et al., 2021). In contrast, mean
468 CA(SiR) intensity remained unaltered, indicating that the capsid remains largely stable
469 under these conditions.


470

471 *Detection of directly labeled HIV-1 capsids in primary cells*

472 To validate our results in a physiologically relevant cell type, primary human CD4⁺ T
473 cells from healthy blood donors were infected, subjected to IF staining against CA, and
474 imaged by SDCM at 24 h p.i. (Figure 6a and Figure S6). We readily detected nuclear
475 subviral SiR positive structures in HIV-1*CA14^{SiR} infected cells, indicating that nuclear
476 replication complexes retained CA also in these primary cells (Figure 6a). Consistent
477 with prior observations made in T cells (Zila et al., 2019) the majority of SiR-positive
478 objects were not associated with CA(IF) signals (9/11 particles; Figure 6a, left) when
479 fixation and immunostaining were performed under standard conditions. As outlined
480 above, treatment with 15 μ M PF74 for 1 h dissociates the large clusters of CPSF6 from
481 nuclear subviral complexes. We observed that this in turn renders nuclear CA
482 accessible for IF detection in T cells, presumably by exposure of CA epitopes upon
483 CPSF6 displacement (Muller et al., 2021). Accordingly, brief PF74 treatment allowed
484 for detection of CA(IF) signals co-localizing with nuclear CA(SiR) punctae (13/16;
485 Figure 6a, right). We conclude that the direct CA labeling strategy presented here
486 overcomes technical artifacts that hamper IF analyses.

487 Further quantitative analyses using primary CD4⁺ T cells prepared from six blood
488 donors revealed similar numbers of nuclear capsid structures in cells infected with HIV-
489 1*CA14^{SiR} than in cells infected with HIV-1* at 24 h p.i. (Figure 6b). SiR intensity
490 measurements were only performed for intranuclear objects in this case since high
491 background due to SiR accumulation in the narrow cytoplasm of T cells precluded
492 reliable analysis of individual particles in the extranuclear region (see Figure 6a and
493 Figure S6). Quantitation of SiR intensities of nuclear punctae in cells infected with an
494 MOI~0.8 yielded similar average intensities as measured in TZM-bl cells
495 (mean=12,485 a.u.), indicating the presence of a complete or nearly complete mature
496 capsid in the nuclear complexes in primary T cells (Figure 6c). Cells infected with an
497 MOI of ~8 displayed higher CA(SiR) intensities of diffraction-limited nuclear objects
498 (mean=39,502 a.u.), suggesting intranuclear clustering of capsids, as observed in
499 TZM-bl cells (Figure 4).

500 Our findings from CA(SiR) intensity measurements argue for the presence of a full
501 capsid complement at subviral structures in the nucleus. These data strengthen
502 conclusions from several recent studies suggesting that the mature capsid lattice may
503 be completely or largely intact on nuclear subviral objects (Burdick et al., 2020; Muller
504 et al., 2021; Zila et al., 2021). However, fluorescence signals do not yield information
505 on the architecture of nuclear CA14^{SiR} containing objects. Therefore, we
506 complemented our analyses by performing CLEM of infected SupT1 T cells. In order
507 to maximize the number of nuclear objects, infection was synchronized by the
508 attachment of particles to the cells for 3 h at a low temperature (16°C) to prevent
509 particle uptake by membrane fusion or endocytosis ((Melikyan et al., 2000; Weigel and
510 Oka, 1981). Virus entry was initiated by temperature shift to 37°C. At 24 h post
511 temperature shift, specimens were prepared by high-pressure freezing (HPF) and
512 freeze substitution, and 250 nm thick resin sections were subjected to SDCM in order
513 to localize CA(SiR) containing structures, followed by correlative electron tomography
514 (CLEM-ET) analysis. CA(SiR) positive objects could be identified by SDCM in the
515 sections (Figure 6d), demonstrating that the brightness of signals derived from direct
516 CA(SiR) labeling is sufficient for CLEM detection of cytosolic and nuclear (sub)viral
517 structures. ROIs were defined based on the SiR signals and subjected to correlative
518 ET analysis. Figure 6e shows an exemplary tomogram obtained from a ROI located
519 within the nucleus. It reveals several closely attached electron-dense structures at the
520 position of the SiR label, whose shape and dimension match those of intact or largely
521 intact mature HIV-1 capsids (Figure 6f and supplementary movie 1). Such structures
522 were recently identified in nuclei of infected cells by CLEM using fluorescently labeled
523 HIV-1 IN as an indirect marker for subviral structures (Muller et al., 2021; Zila et al.,
524 2021) and were interpreted as capsid shells based on their morphology. Here we
525 demonstrate that such structures co-localize with nuclear foci comprising a high
526 number of click labeled CA molecules, thereby providing direct evidence that the cone-
527 shaped objects are HIV-1 capsids that have entered the nucleus of infected cells.



528

529 **Figure 6. Largely complete click labeled capsid structures detected in the nucleus of**
 530 **primary CD4⁺ T cells and T cell line. (a)** Activated CD4⁺ T cells were infected with HIV-
 531 1*CA14^{SiR} (MOI~0.8) for 24 h before DMSO/PF74 treatment for 1 h, fixation, and methanol
 532 extraction. Samples were immunostained against CA (green) and laminaA (blue). Images show
 533 a single z slice through the cell. Enlargements show the particle marked by the arrowhead.
 534 Scale bars: 10 μ m (overview) and 1 μ m (enlargement). **(b)** Data analyzed from the experiment
 535 outlined in (a). The graph shows the number of CA positive foci per nucleus in cells infected
 536 with HIV-1* (n=35 cells, mean=0.85) or HIV-1*CA14^{SiR} (n= 73 cells, mean=0.51). Pooled data
 537 from 6 different blood donors are shown. Grey lines show median and interquartile lines. **(c)**
 538 CA(SiR) intensities of nuclear objects in infected and activated CD4⁺ T cells at an MOI~0.8
 539 (n=13; mean=12,485 \pm 7,445 a.u.) and an MOI ~8 (n=7; mean=39,502 \pm 18,025 a.u.). MOI
 540 was determined in TZM-bl cells. Grey lines show median and interquartile lines. **(d-f)** Nuclear
 541 cone-shaped capsids detected by CLEM-ET. SupT1 cells were treated with 1 μ M aphidicolin
 542 (APC) for 16 h to prevent cell division, before infection with HIV-1*CA14^{SiR} virions (2.3 μ U
 543 RT/cell, corresponds to an MOI~0.4 determined in TZM-bl cells). At 24 h p.i., cells were cryo-

544 *immobilized by high-pressure freezing, freeze substituted, and further processed for CLEM*
545 *and ET as described in materials and methods. (d) SDCM image of a 250-nm thick resin*
546 *section of the cell infected with HIV-1*CA14^{SIR} virions (magenta), post-stained with Hoechst*
547 *(blue) and decorated with multi-fluorescent fiducials (Fd) for correlation. The arrowhead in the*
548 *enlargement of the boxed region indicates a CA(SiR) signal within the Hoechst-stained nuclear*
549 *region. Scale bars: 1 μ m (overview) and 200 nm (enlargement). (e) Computational slices*
550 *through tomographic reconstructions at the correlated region boxed in (d) with views*
551 *highlighting the presence of clustered capsid-reminiscent structures (black arrowheads) in the*
552 *nuclear region. Nu, nucleus; NPC, nuclear pore complex; NE, nuclear envelope. Scale bar:*
553 *100 nm. (f) Segmented and isosurface rendered structure of the cones detected in (e).*
554 *Magenta: capsid, yellow: NE, cyan: NPC (cryo-EM map of NPC: EMD-11967 (Zila et al.,*
555 *2021)). See also supplementary movie 1.*

556

557 **Discussion**

558 Here we present a direct labeling approach for the HIV-1 CA protein that yields
559 infectious and morphologically mature viral particles. The minimally invasive GCE/click
560 labeling approach used here represents an ideal strategy for the versatile labeling of
561 genetically fragile viral capsid proteins in principle, but its potential for virus imaging
562 has not been fully exploited. GCE has previously been explored to generate
563 conditionally replication-competent live attenuated viruses as vaccine candidates (Si
564 et al., 2016; Yuan et al., 2017). The combination of GCE and subsequent
565 functionalization of a viral capsid protein by click chemistry has so far only been applied
566 to the non-enveloped adeno-associated virus (AAV) (e.g., (Kelemen et al., 2018;
567 Zhang et al., 2018). However, the capsid of AAV, unlike HIV-1 CA, can tolerate peptide
568 insertions and larger modifications (e.g., (Borner et al., 2020; Chandran et al., 2017;
569 Feiner et al., 2019; Varadi et al., 2012). Here, we demonstrate that GCE in conjunction
570 with click labeling can also be applied to an enveloped virus with a highly
571 multifunctional and extremely genetically fragile capsid protein. All previously
572 described genetic tagging strategies for HIV-1 CA (Burdick et al., 2020; Campbell et
573 al., 2008; Pereira et al., 2011; Zurnic Bonisch et al., 2020) require complementation
574 with a molar excess of wt protein or virus. Since the mature HIV-1 capsid is assembled
575 from less than half of the ~2,500 CA molecules packaged in the virion (Briggs et al.,
576 2004; Lanman et al., 2004), it cannot be ascertained in this case whether the subset
577 of genetically tagged CA molecules is an integral part of the mature capsid lattice. In

578 contrast, we found that the strategy described here allowed genetic labeling of HIV-1
579 CA in the proviral context while retaining infectivity in the absence of complementation.

580 The detection of a label covalently attached to CA is independent of cellular context,
581 sample treatment, or exposure of CA epitopes. Thereby, the method overcomes
582 limitations of IF detection that had previously resulted in different conclusions regarding
583 the presence of CA on subviral complexes. The use of synthetic dye molecules also
584 renders the labeling strategy compatible with a wide range of fluorescence imaging
585 approaches, including live-cell microscopy, correlative imaging and super-resolution
586 fluorescence microscopy techniques (Wang et al., 2019).

587 Our approach allowed for direct, quantitative analysis of containing objects and CA
588 amounts associated with viral complexes in microscopic images of infected cells. While
589 time-lapse experiments showed some delay in nuclear import kinetics for labeled
590 capsid-like objects, the infectivity of highly labeled preparations was reduced by only
591 twofold, and the number of nuclear objects reached was similar to that detected in cells
592 infected with wt virus. Thus, site-specific introduction of a synthetic fluorophore can be
593 compatible with capsid functionality in HIV-1 post-entry processes. CA amounts
594 approximately corresponding to a full complement of a mature capsid were found to
595 be associated with subviral complexes in nuclei of a HeLa-derived cell line and primary
596 human CD4⁺ T cells, also upon inhibition of cell division by aphidicolin treatment. By
597 applying correlative imaging, we provide direct evidence that nuclear capsid-shaped
598 objects, as recently detected by correlative ET before and after separation of the viral
599 genome from the bulk of viral proteins (Muller et al., 2021; Zila et al., 2021) indeed
600 represent HIV-1 capsids or capsid-like remnants. Taken together, these results argue
601 against (partial) capsid uncoating prior to entering the nucleoplasm, as had been
602 concluded earlier based on low or lacking CA IF signals associated with nuclear
603 subviral complexes in certain cell types (e.g. (Burdick et al., 2017; Hulme et al., 2015;
604 Peng et al., 2014; Zila et al., 2019), or based on the loss of the fluorescently labeled
605 capsid binding protein CypA at the nuclear envelope ((Francis et al., 2016); Francis
606 2018; Francis and Melikyan 2020). The apparent discrepancy between these previous
607 IF results and data from direct CA quantification may be explained by differential
608 accessibility of capsid epitopes under different IF conditions. The indirect label CypA,
609 on the other hand, might be displaced from capsids at the nuclear pore, possibly by
610 competition between fluorescent CypA and the outer NPC protein Nup358, which also
611 carries a binding site for the CypA binding loop of CA (Schaller et al., 2011). Our data

612 suggest nuclear capsid uncoating in a model cell line, as well as in primary T cells, in
613 agreement with recent findings from us and others, which indicated that the nuclear
614 pore channel is wider than assumed earlier, allowing HIV-1 capsids to pass the intact
615 NPC (Zila et al., 2021), and that HIV-1 uncoating occurs after nuclear import (Burdick
616 et al., 2020; Dharan et al., 2020; Li et al., 2021; Selyutina et al., 2020), apparently by
617 separation of the viral genome from a broken capsid remnant (Muller et al., 2021).

618 Small clusters of CA positive objects were detected by STED nanoscopy in nuclei of
619 TZM-bl cells, consistent with the reported detection of nuclear clusters containing
620 multiple HIV-1 replication complexes (Francis et al., 2020b), multiple viral genomes
621 (Rensen et al., 2021), or even several intact or partly intact capsid-like structures
622 (Muller et al., 2021) in various cell types. Our analyses revealed that the observed
623 clustering is dependent on the amount of virus used for infection. Most nuclear signals
624 represented single capsids at a lower MOI, whereas frequent clustering was observed
625 at high MOI. This observation suggests that capsids enter the nucleus individually, but
626 traffic via a limited number of routes and accumulate at defined sites of uncoating. This
627 raises the question whether HIV-1 capsids use a 'specialized' subset of nuclear pores
628 for nuclear entry; the answer would not only be relevant in the context of HIV-1
629 replication, but also with respect to an understanding of the nuclear import process.
630 Intracellular Nup levels and presumably NPC composition have been reported to
631 influence HIV-1 replication (Kane et al., 2018), but compositional and structural
632 variability of NPCs between different cell types, or within an individual cell, is
633 incompletely understood (reviewed in (Knockenbauer and Schwartz, 2016)). The route,
634 mechanism and functional consequences of intranuclear trafficking of HIV-1
635 complexes also warrant further analysis. Growing evidence from recent studies
636 suggests that incoming viral replication complexes accumulate at nuclear speckles in
637 a CA and CPSF6-dependent manner, and that reverse transcription may only be
638 completed near the site of integration (Burdick et al., 2020; Francis et al., 2020a;
639 Rensen et al., 2021; Selyutina et al., 2020). Combining the direct CA labeling described
640 here with the recently developed fluorescence detection of the reverse transcribed
641 genome (Blanco-Rodriguez et al., 2020; Muller et al., 2021) will provide us with the
642 possibility to study the uncoating process in more detail using a combination of
643 confocal imaging, nanoscopy, and correlative imaging.

644 The direct labeling approach also allowed us to investigate the effect of the capsid
645 inhibitor PF74 (Blair et al., 2010), whose detailed mode of action is still under

646 investigation, on nuclear capsids. We found that displacement of CPSF6 from nuclear
647 subviral structures was not accompanied by a loss of CA signal. This finding disagrees
648 with the recently reported rapid CA dissociation from nuclear complexes upon PF74
649 addition, that was based on imaging of HIV-1 particles containing eGFP-CA
650 complemented by a molar excess of wt CA (Burdick et al., 2020). The apparent
651 discrepancy may suggest that the subset of eGFP-tagged CA molecules is not an
652 integral part of the mature capsid lattice, resulting in premature loss of the labeled
653 molecules. Our findings are in line with the observation that PF74 treatment does not
654 lead to a loss of CA IF signal on nuclear complexes but rather enhances
655 immunostaining efficiency ((Francis et al., 2020b; Muller et al., 2021)) and with *in vitro*
656 findings that indicate breakage of lattice integrity by PF74, but stabilization of the
657 remaining lattice (Marquez et al., 2019; Rankovic et al., 2018).

658 In conclusion, direct click labeling of HIV-1 CA is a versatile approach that substantially
659 expands the possibilities to study the early events in HIV-1 replication with high
660 temporal and/or spatial resolution using advanced fluorescence microscopy methods.
661 Application for the HIV-1 CA provided direct proof that the capsid stays largely intact
662 upon passage of the subviral complex into the nucleus and directly identified nuclear
663 capsid-like structures that morphologically resembled the virion capsid by CLEM-ET.
664 The fact that the combination of GCE and click chemistry could successfully be applied
665 to a notoriously genetically fragile capsid protein of an enveloped virus opens the
666 perspective that this strategy may also advance and expand fluorescence labeling of
667 a broad range of other viruses.

668

669 **Acknowledgements**

670 We acknowledge microscopy support from the Infectious Diseases Imaging Platform
671 (IDIP) at the Center for Integrative Infectious Disease Research, Heidelberg. We thank
672 Eyal Arbely (The National Institute for Biotechnology in the Negev, Beer-Sheva, Israel)
673 for providing pEA168. pNESPyIRS-eRF1dn-tRNA was kindly provided by Anna-Lena
674 Schäfer (University Hospital Heidelberg, Heidelberg, Germany).

675 This work was funded by the Deutsche Forschungsgemeinschaft (DFG; German
676 Research Foundation), Projektnummer 240245660, SFB 1129 project 6 (B.M.) and
677 project 5 (H.G.K.).

678

679

680 **Materials and Methods**

681 **Plasmids**

682 Plasmids were cloned using standard molecular biology techniques and verified by
683 commercial Sanger sequencing (Eurofins Genomics). PCR was performed using Q5
684 High-Fidelity DNA Polymerase (New England Biolabs) or Phusion DNA Polymerase
685 (New England Biolabs) according to the manufacturer's instructions using primers
686 purchased from Eurofins Genomics. Plasmid amplification was carried out in *E. coli*
687 Stbl2 (Thermo Fisher Scientific) cells.

688 HIV-1 plasmids were based on the proviral plasmid pNLC4-3 (Bohne and Krausslich,
689 2004) that expresses the authentic genomic RNA from HIV-1_{NL4-3} (Adachi et al., 1986)
690 under the control of the cytomegalovirus promoter. To avoid unwanted ncAA
691 incorporation into the virion component Vpr, the amber stop codon of the *vpr* ORF of
692 pNLC4-3 was mutated into an opal stop codon (TGA) via site-directed mutagenesis.
693 See primer list for sequences of primers used. PCR1 (primers Vpr_{TGA} a and Vpr_{TGA} b)
694 and PCR2 (primers Vpr_{TGA} c and Vpr_{TGA} d) were performed in parallel to generate two
695 overlapping single stranded PCR products. Using a combination of both products of
696 these reactions as new templates, PCR3 with primers Vpr_{TGA} a and Vpr_{TGA} d resulted
697 in PCR fragments comprising the respective mutation. These fragments were
698 subcloned into pNLC4-3 using unique PflMI/NheI restriction sites, resulting in pNLC4-
699 3* (HIV-1*).

700 To allow for site-specific GCE the codon for amino acid A14 of CA was mutated into
701 TAG via overlap PCR. PCR1 (primers CA14_{BssHII} fwd 1, CA14_{TAG} rev 1) and PCR2
702 (primers CA14_{TAG} fwd 2, CA14_{Apal} rev 2) were performed in parallel to generate two
703 overlapping single-stranded PCR products. PCR3 with primers CA14_{BssHII} fwd 1 and
704 CA14_{Apal} rev 2 result in the PCR fragment comprising the mutation, which was
705 subcloned into pNLC4-3* using unique BssHII/Apal restriction sites, resulting in
706 pNLC4-3*CA14^{TAG} (HIV-1*CA14^{TAG}).

707 Plasmid pNESPylRS-eRF1dn-tRNA (Schifferdecker, Sakin et al., in preparation) is
708 based on pEA168 ((Cohen and Arbely, 2016), kindly provided by Eyal Arbely, Ben-
709 Gurion University of the Negev, Israel), a eukaryotic vector that comprises expression
710 cassettes for two proteins and four tRNA molecules. The coding sequence for a
711 modified pyrrolysine tRNA synthetase was PCR amplified from plasmid
712 tRNA^{Pyl}/NESPylRS^{AF} (Nikic et al., 2016) and cloned into a CMV promoter driven

713 cassette in pEA168 using HindIII/XbaI restriction sites, resulting in plasmid pEA168-
714 CMV-aaRS-4xU6tRNA. A PCR fragment encoding a dominant version of the
715 eukaryotic release factor 1 (eRF1(E55D)) amplified from plasmid pERF1-E55D
716 (Schmied et al., 2014) was subsequently inserted into an expression cassette driven
717 by the EF1 promoter into pEA168-CMV-aaRS-4xU6tRNA using KpnI/MluI restriction
718 sites, yielding pNESPylRS-eRF1dn-tRNA.
719

primer	sequence
Vp _{RTGA} a	ctggcatttgggtcagggagtc
Vp _{RTGA} b	cagggctctagttcaggatctactggctc
Vp _{RTGA} c	gagccagtagatcctgaactagagccctg
Vp _{RTGA} d	gttctctaatttgctagc
CA A14 _{BssHII} fwd 1	cttgctgaagcgcgca
CA A14 _{TAG} rev 1	agttctaggtgatatctactgatgtaccattg
CA A14 _{TAG} fwd 2	caaatggtagatcagtagatcacctagaact
CA A14 _{ApaI} rev 2	gcctgcaatttttgctatgtg

720

721 **Cell culture**

722 HEK293T (Pear et al., 1993) and HeLa TZM-bl indicator cells (Wei et al., 2002) were
723 maintained in Dulbecco's Modified Eagle's medium (Thermo Fisher Scientific)
724 supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin (PAN Biotech, GER)
725 and 10% fetal calf serum (FCS, Sigma Aldrich, USA). Both cell lines were regularly
726 monitored for mycoplasma contamination using the MycoAlert mycoplasma detection
727 kit (Lonza Rockland, USA). Primary CD4+ T cells were cultured in RPMI 1640
728 containing L-glutamine supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin
729 (PAN Biotech), 10% heat-inactivated FCS, and 5% human AB serum (Sigma Aldrich).

730

731 **Isolation of primary cells**

732 Primary human CD4+ T cells were isolated from buffy coats obtained from healthy and
733 anonymous blood donors at the Heidelberg University Hospital Blood Bank following
734 the regulations of the local ethics committee. CD4+ T cells were isolated using
735 EasySep™ Direct Human T Cell Isolation Kit (Stemcell technologies, GER) according
736 to the manufacturer's instructions and activated by incubation in the presence of 100
737 U/ml IL-2 (Sigma Aldrich) and T Cell TransAct™ human (Miltenyi Biotec, GER) for 72
738 h.

739

740 **Virus particle production**

741 HEK293T cells were seeded in T175 tissue culture flasks the day before (~15 Mio.
742 cells) and transfected using calcium phosphate precipitation according to standard
743 procedures (~80 % confluency). Cells were co-transfected with 50 µg / flask total DNA
744 of pNLC4-3* (HIV-1*) or pNLC4-3*CA14^{TAG} (HIV-1*CA14^{TAG}) and plasmid
745 pNESPyIRS-eRF1dn-tRNA in a molar ratio of 2.22:1. At 6 h p.t., medium was removed,
746 and fresh complete DMEM containing a final concentration of 500 µM CpK (SiChem;
747 stock solution of 100 mM was pre-diluted 1:4 in 1M HEPES shortly before use), and
748 100 µM ascorbic acid (Sigma Aldrich; stock solution 10 mM) was added. At 48 h p.t.
749 the tissue culture supernatant was harvested and filtered through 0.45 µm
750 nitrocellulose filters. For labeling the CA protein, 250 nM Tetrazine-SiR (Spirochrome;
751 stock solution 1 mM) was added to the filtered supernatant, and samples were
752 incubated at 37°C for 30 min. Particles were then concentrated by ultracentrifugation
753 through a 20% (w/v) sucrose cushion at 28,000 rpm using a Beckman TLA-100 fixed
754 angle-rotor (Beckman Coulter, GER) for 90 min at 4°C. Pellets were gently
755 resuspended in phosphate-buffered saline (PBS) containing 10% FCS and 10 mM
756 HEPES (pH 7.5) and stored in 5 µl aliquots at -80°C.

757

758 **Immunoblotting and In-gel fluorescence**

759 Virus samples were mixed 1:10 with SDS sample buffer (150 mM Tris HCl, pH 6.8, 6%
760 (w/v) SDS, 30% Glycerin, 0.06% bromophenol blue, 20% β -Mercaptoethanol) and
761 boiled at 95°C for 15 min. 10 µl HIV-1* and 40 µl HIV-1*CA^{SiR} lysates were subjected
762 to SDS-PAGE (15 %; acrylamide:bisacrylamide 200:1). Cell lysates were generated
763 from transfected HEK293T cells. At 40 h p.t. cells were washed with PBS, trypsinized
764 and resuspended in PBS. 1 ml of cell suspension was mixed with 300 µl SDS sample
765 buffer and boiled at 95°C for 15 min. 10 µl cell lysate was subjected to SDS-PAGE.
766 Proteins were transferred to a nitrocellulose membrane (Millipore) by semi-dry blotting
767 for 1 h at 0.8 mA/cm². Viral antigens were stained with the indicated antisera in
768 PBS/0.5% bovine serum albumin (BSA) (sheep αCA, polyclonal 1:5 (in-house); rabbit
769 αMA, polyclonal 1:1,000 (in-house); rabbit αRT, polyclonal, 1:1,000 (in-house), mouse
770 αaminA/C, monoclonal antibody 1:100 (Cat# sc-7292, Santa Cruz Biotechnology),
771 mouse αaminB1, monoclonal 1:100 (Cat# sc-365962, Santa Cruz Biotechnology))
772 followed by staining with corresponding secondary antibodies IRDyeTM in PBS/0.5%
773 BSA (anti-sheep 680CW (1;10,000); Rockland, or anti-rabbit 800CW (1:10,000); Li-

774 COR Biosciences). Detection was performed using a Li-COR Odyssey CLx infrared
775 scanner (Li-COR Biosciences) according to manufacturer's instructions. CA
776 quantification was performed with ImageStudio LITE software (Li-COR Biosciences)
777 via intensity measurements of CA bands and a serial dilution of recombinant purified
778 CA standard (2.5 ng/ μ l; in-house) on the same membrane. For in-gel fluorescence, the
779 acrylamide gels were directly scanned using a Li-COR Odyssey CLx infrared scanner
780 (Li-COR Biosciences) set at an emission wavelength of 700 nm.

781

782 **Infectivity assay**

783 Virus amounts were quantified via SYBR Green based Product Enhanced Reverse
784 Transcription assay (SG-PERT; (Pizzato et al., 2009)). To determine the effect of
785 incorporating CpK and Tet-SiR labeling on virus infectivity, HIV-1* and HIV-1*CA14^{SiR}
786 viral particles (normalized by RT activity) were titrated on TZM-bl cells seeded in 15-
787 well ibidi μ -Slide angiogenesis dishes. At 6 h p.i. 50 μ M T-20 (Enfuvirtide; Roche, GER;
788 stock solution 20 mM) was added to prevent second-round infection. Infection rates
789 were scored at 48 h p.i.. For this, cells were fixed in 4% paraformaldehyde (PFA;
790 Electron Microscopy Sciences, USA; stock solution 16%) for 15 min, followed by 20
791 min incubation in PBS/0.5% (v/v) Triton X-100 at room temperature. Immunostaining
792 was performed using an in-house polyclonal rabbit antiserum raised against
793 recombinant HIV-1 MA (1:1000) in PBS/0.5% BSA) 1 h at room temperature.
794 Secondary antibody Alexa Fluor 488 donkey anti-rabbit (1:1,000; Thermo Fisher
795 Scientific) in PBS/0.5% BSA was added for 45 min at room temperature. Samples were
796 imaged by SDCM. The mean intensity of the 488 channel (MA(IF)) was quantified in
797 from the non-infected samples imaged in parallel and subtracted as background in
798 each image. The proportion of IF-positive cells was counted in 12 randomly selected
799 fields of view using Fiji (Schindelin et al., 2012). To determine the infectivity of virus
800 particle preparations, the number of infected cells per well was calculated by
801 multiplying the percentage of infected cells detected with the number of cells per well
802 (double of seeded cell number the day before). Division by the volume of virus
803 suspension used for infection yielded the number of infectious units (IU) / ml.

804

805 **Fixation and immunofluorescence staining of infected cells**

806 3.33×10^3 TZM-bl cells were seeded into 15-well μ -Slides angiogenesis dishes (ibidi,
807 GER; cat. 81507) the day before infection. Infection at 37°C was performed with an

808 MOI ~0.8 for 6,9,12 or 18 h. Subsequently, cells were incubated for 1 h with 15 μ M
809 PF74 (Sigma Aldrich; stock solution 10 mM in DMSO) in DMEM to allow for efficient
810 detection of nuclear CA by IF (Muller et al., 2021). Samples were washed with PBS,
811 fixed in 4% PFA for 15 min and permeabilized with PBS/0.5% (v/v) Triton-X100 for 20
812 min, and washed again with PBS. Cells were extracted using ice-cold 100% methanol
813 for 10 min. Afterward, samples were blocked with PBS/2.5% BSA for 15 min, followed
814 by incubation with primary antibodies in PBS/0.5% BSA for 1 h at room temperature.
815 After washing three times with PBS, secondary antibodies diluted in PBS/0.5% BSA
816 were added for 45 min at room temperature. Samples were washed and stored in PBS
817 at 4°C. For infection of primary CD4⁺ T cells, 20,000 cells were infected with HIV-1* or
818 HIV-1*CA14^{SiR} in a 96-well v-bottom microplate (Greiner Bio-one, cat. #650161) in a
819 volume of 40 μ l RPMI and transferred at 22 h p.i. onto a PEI-coated 15-well μ -Slide
820 angiogenesis dishes (ibidi). Cells were allowed to adhere for 1 h at 37°C, and PF74
821 diluted in fresh growth medium was added to a final concentration of 15 μ M. Extraction,
822 fixation, and immunostaining were performed after 1 h at 37°C as described above.
823 For the detection of endosome-associated particles, 2 μ M mCLING ATTO488
824 (Synaptic Systems; stock 50 μ M) was added to TZM-bl cells seeded in 15-well μ -Slides
825 Angiogenesis and incubated at 16°C for 30 min. Subsequently, the fluorescent probe
826 was removed, HIV-1*CA14^{SiR} particles were added in fresh growth medium, and cells
827 were incubated for an additional 3 h at 37°C (MOI~0.8). Cells were fixed for 90 min at
828 room temperature in 4% PFA and 0.2% glutaraldehyde to ensure retention of mCLING
829 at cellular membranes. Nuclei were stained with 5 μ g/ml Hoechst (Merck) in PBS for
830 30 min.

831

832 **Cell viability assay**

833 To test the effect of mCLING ATTO488 (Synaptic Systems) staining on cell viability,
834 TZM-bl cells were seeded into a 96-well plate (9×10^3 cells/well; flat bottom Greiner Bio-
835 one) the day before and incubated in medium supplemented with the indicated
836 concentration of mCLING ATTO488 for 30 min at 16°C. After staining, cells were
837 trypsinized, stained with Trypan blue using standard procedures and analyzed with a
838 TC20TM Automated Cell Counter (BioRad).

839

840 **Labelling efficiency of immobilized particles**

841 15-well μ -Slide angiogenesis dishes (ibidi) were coated with 30 μ l/well
842 polyethyleneimine (PEI; 1mg/ml) for 30 min at room temperature and washed with
843 PBS. Pre-labeled HIV-1* and HIV-1*CA14^{SiR} particles were incubated in PBS on PEI-
844 coated microscopy slides for 1 h at 37°C. Subsequently, samples were washed with
845 PBS, fixed in 4% PFA for 15 min and permeabilized with PBS/0.05% (v/v) Triton X-100
846 for 20 min at room temperature. Immobilized particles were blocked with PBS/2.5%
847 BSA for 15 min and polyclonal rabbit antiserum raised against recombinant HIV-1 CA
848 protein (in-house) was added (1:1000 in PBS/0.5% BSA for 1 h at room temperature).
849 After washing three times with PBS, secondary antibody Alexa Fluor 488 donkey anti-
850 rabbit (Thermo Fisher Scientific) 1:1000 in PBS/0.5% BSA was added for 45 min at
851 room temperature. Samples were washed and stored in PBS at 4°C.

852

853 **Confocal microscopy (SDCM)**

854 Multichannel z-series with a z-spacing of 200 nm, spanning the whole cell volume (3D),
855 were acquired using a PerkinElmer Ultra VIEW VoX 3D spinning disk confocal
856 microscope (SDCM; Perkin Elmer). A 60x oil immersion objective (numeric aperture
857 [NA] 1.49; Perkin Elmer) was used for imaging of TZM-bl cells or 100x oil immersion
858 objective ([NA] 1.49; Perkin Elmer) for primary CD4+ T cells and immobilized particles.
859 Images were recorded in the 405-, 488-, 561-, and 640 nm channels.

860

861 **STED microscopy**

862 STED nanoscopy was performed using a $\lambda = 775$ nm STED system (Abberior
863 Instruments GmbH) equipped with a 100x oil immersion objective (NA 1.4; Olympus
864 UPlanSApo). STED images were acquired using the 640 nm excitation laser lines while
865 the 488 and 590 laser line was acquired in confocal mode only. Nominal STED laser
866 power was set to 20% of the maximal power (1250 mW) with pixel dwell time of 10 μ s
867 and 15 nm pixel size. STED images were deconvolved using the software Inspector
868 (Abberior Instruments GmbH) and Huygens Professional Deconvolution (Scientific
869 Volume Imaging).

870

871 **Electron microscopy**

872 HEK293T cells (4×10^5) were seeded in a glass coverslip-bottom petri dish (MatTek,
873 MA, USA), cultured for 16 h at 37°C and then co-transfected with pNLC4-3*CA14^{TAG}
874 and pNESPyIRS-eRF1dn-tRNA by using calcium phosphate precipitation. At 6 h p.t.,

875 medium was removed and fresh complete DMEM containing a final concentration of
876 500 μM CpK (SiChem; stock solution 100 mM was pre-diluted 1:4 in 1M HEPES shortly
877 before use), and 100 μM ascorbic acid (Sigma Aldrich; stock solution 10 mM) was
878 added. At 44 h p.t., cells were fixed with pre-warmed 2% formaldehyde + 2.5%
879 glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) for 1.5 h at room temperature, then
880 washed in 0.1 M cacodylate buffer and post-fixed with 2% osmium tetroxide (Electron
881 Microscopy Sciences) for a 1 h on ice. Cells were subsequently dehydrated through
882 an increasing cold ethanol series (30, 50, 70, 80, 90, and 100%; on ice) and two
883 anhydrous acetone series (at room temperature). The coverslip with cells was then
884 removed from the dish, and cells were flat embedded in Epon resin. 70-nm thin
885 sections were cut with an ultramicrotome (Leica EM UC6), collected on formvar-coated
886 100-mesh copper EM grids (Electron Microscopy Sciences) and stained with a 3%
887 uranyl acetate in 70% MeOH (10 min), and lead citrate (7 min). Cells sections were
888 observed with a JEOL JEM-1400 electron microscope operating at 80 kV (Jeol Ltd.,
889 JPN), equipped with a bottom-mounted 4K by 4K pixel digital camera (TemCam F416;
890 TVIPS GmbH, GER).

891

892 **CLEM and electron tomography**

893 SupT1 cells were distributed in a 96-well plate (2×10^5 cells/well; U-bottom; Greiner Bio-
894 one, 650180) and pre-incubated for 16 h with 1 μM aphidicolin (APC; Merck). Cells
895 were pelleted (200 x g, 3 min) and resuspended in complete RPMI medium containing
896 HIV-1*CA14^{SIR} particles (MOI~0.4). Cells were incubated with viral particles for 120
897 min at 16°C to adsorb the virus and synchronize virus entry. Samples were then
898 processed for CLEM and ET as described previously (Zila et al., 2021). In brief, cells
899 were transferred to glass-bottomed 'microwell' of a MatTek dish (MatTek, USA)
900 containing carbon-coated and retronectin-coated sapphire discs (Engineering Office
901 M. Wohlwend, SUI). Samples were high pressure frozen, and sapphire discs were then
902 transferred from liquid nitrogen to the freeze-substitution (FS) medium (0.1% uranyl
903 acetate, 2.3% methanol and 2% H₂O in acetone) tempered at -90°C. Samples were
904 FS-processed and embedded in Lowicryl HM20 resin (Polysciences, USA) according
905 to a modified protocol of Kukulski et al. (Kukulski et al., 2011). For CLEM-ET, thick
906 resin sections (250 nm) were cut and placed on a slot (1 x 2 mm) EM copper grids
907 covered with a formvar film (Electron Microscopy Sciences, FF2010-Cu). Grids were
908 decorated with fiducial marker and stained with Hoechst to visualize nuclear regions.

909 Light microscopy Z stacks of sections were acquired by PerkinElmer UltraVIEW VoX
910 3D Spinning-disc Confocal Microscope (Perkin Elmer) using a 100 × oil immersion
911 objective (NA 1.49; Nikon), with a z-spacing of 200 nm and excitation with the 405-,
912 488-, 561- and 633-nm laser line. Acquired z stacks were visually examined using Fiji
913 software (Schindelin et al., 2012) and intracellular CA(SiR) positive signals were
914 identified. EM grids were decorated with 15 nm protein-A gold particles for tomogram
915 alignment and stained with uranyl acetate and lead citrate. Grids were loaded to a
916 Tecnai TF20 (FEI) electron microscope (operated at 200 kV) equipped with a field
917 emission gun and a 4K by 4K pixel Eagle CCD camera (FEI). Positions of CA(SiR)
918 signals were pre-correlated with imported SDCM images in SerialEM as described
919 previously (Schorb et al., 2017). Single-axis electron tomograms were carried out.
920 Tomographic tilt ranges were typically from -60° to 60° with an angular increment of
921 1° . The pixel size was 1.13 nm. Alignments and 3D reconstructions of tomograms were
922 done with IMOD software (Kremer et al., 1996). Post-correlation was performed using
923 eC-CLEM plugin in Icy software (de Chaumont et al., 2012).

924

925 **Image analysis**

926 Microscopy images were screened and filtered in Fiji/ImageJ (Schindelin et al., 2012)
927 with a mean filter and background subtraction. Infected cells were quantified in Fiji via
928 segmentation and counting of nuclei and the cell counter to manually quantify the
929 number of positive cells. To determine labeling efficiency of click labeled particles,
930 CA(SiR) intensities of detected immobilized particles based on CA(IF) were quantified
931 using the spot detector of the software Icy (de Chaumont et al., 2012). Five ROIs
932 without particles were measured, and mean intensity in the SiR channel was
933 subtracted as background. The threshold was set to $t = 1,000$ a.u.. CA(IF) detected
934 spots with intensities above the threshold were classified as CA(SiR) positive.

935 To analyze particle distribution and intensity measurements throughout the entire
936 volume of cells, z-image series were reconstructed in 3D space using Imaris 9.2
937 software (Bitplane AG). Individual HIV-1 CA(IF) objects were automatically detected
938 using the spot detector Imaris module, which created for each fluorescent signal a 3D
939 ellipsoid object with 300 nm estimated diameter in x-y dimensions and 600 nm in z.
940 The local background of each individual spot was subtracted automatically.
941 Subsequently, the mean signal intensity in the CA(SiR) channel was quantitated within
942 all objects. The threshold for SiR intensity was set to $t = 7,000$ a.u. and adjusted

943 manually for each image by visual inspection. Spots detected in SiR-clusters were
944 excluded. Nuclear objects were manually identified based on the laminA/C staining.
945 NE-associated objects were classified based on laminA/C intensities. Every image was
946 manually inspected and a threshold for NE-associated objects was set in the range of
947 6,300-9,100 a.u.. All other particles were classified as PM/cytoplasm (= in the
948 cytoplasm/at plasma membrane).

949 To identify post-fusion cores by mCLING ATTO488 staining, HIV-1 CA(SiR) positive
950 objects were automatically detected and the mCLING ATTO488 mean signal intensity
951 co-localizing with each object was quantitated. The threshold was set to $t = 5,900$ a.u.
952 based on the lowest mCLING intensity detected in a T-20 control sample. Particles
953 associated with mCLING intensity above background were classified as endosome
954 associated. Fiji standard 'greyscale' lookup table (LUT) was used to visualize single
955 channel images and 'Fire' for single channel STED images.

956

957 **Data visualization and statistical analysis**

958 Statistical significance was assessed using Prism v9.1.0 (GraphPad Software Inc,
959 USA). A two-tailed non-paired Mann-Whitney test ($\alpha = 0.05$) was used to assess the
960 statistical significance of non-parametric data. Data were plotted using Prism v9.1.0 or
961 the Python statistical data visualization package seaborn v.0.10.0 (Waskom 2020)
962 Graphs show mean/median with error bars as defined in the figure legends.

963

964 **Competing financial interests:** The authors declare no competing financial interests.

965

966

967

968

969

970

971

972

973

974 **References**

- 975
976 Adachi, A., Gendelman, H.E., Koenig, S., Folks, T., Willey, R., Rabson, A., and Martin, M.A.
977 (1986). Production of acquired immunodeficiency syndrome-associated retrovirus in human
978 and nonhuman cells transfected with an infectious molecular clone. *Journal of virology* *59*,
979 284-291.
- 980 Aiken, C., and Rousso, I. (2021). The HIV-1 capsid and reverse transcription. *Retrovirology*
981 *18*, 29.
- 982 Blair, W.S., Pickford, C., Irving, S.L., Brown, D.G., Anderson, M., Bazin, R., Cao, J.,
983 Ciaramella, G., Isaacson, J., Jackson, L., *et al.* (2010). HIV capsid is a tractable target for
984 small molecule therapeutic intervention. *PLoS pathogens* *6*, e1001220.
- 985 Blanco-Rodriguez, G., Gazi, A., Monel, B., Frabetti, S., Scoca, V., Mueller, F., Schwartz, O.,
986 Krijnse-Locker, J., Charneau, P., and Di Nunzio, F. (2020). Remodeling of the Core Leads
987 HIV-1 Preintegration Complex into the Nucleus of Human Lymphocytes. *Journal of virology*
988 *94*.
- 989 Bohne, J., and Krausslich, H.G. (2004). Mutation of the major 5' splice site renders a CMV-
990 driven HIV-1 proviral clone Tat-dependent: connections between transcription and splicing.
991 *FEBS letters* *563*, 113-118.
- 992 Borner, K., Kienle, E., Huang, L.Y., Weinmann, J., Sacher, A., Bayer, P., Stullein, C.,
993 Fakhiri, J., Zimmermann, L., Westhaus, A., *et al.* (2020). Pre-arrayed Pan-AAV Peptide
994 Display Libraries for Rapid Single-Round Screening. *Molecular therapy : the journal of the*
995 *American Society of Gene Therapy* *28*, 1016-1032.
- 996 Briggs, J.A., Simon, M.N., Gross, I., Krausslich, H.G., Fuller, S.D., Vogt, V.M., and Johnson,
997 M.C. (2004). The stoichiometry of Gag protein in HIV-1. *Nature structural & molecular*
998 *biology* *11*, 672-675.
- 999 Briggs, J.A., Wilk, T., Welker, R., Krausslich, H.G., and Fuller, S.D. (2003). Structural
1000 organization of authentic, mature HIV-1 virions and cores. *The EMBO journal* *22*, 1707-
1001 1715.
- 1002 Burdick, R.C., Delviks-Frankenberry, K.A., Chen, J., Janaka, S.K., Sastri, J., Hu, W.S., and
1003 Pathak, V.K. (2017). Dynamics and regulation of nuclear import and nuclear movements of
1004 HIV-1 complexes. *PLoS pathogens* *13*, e1006570.
- 1005 Burdick, R.C., Li, C., Munshi, M., Rawson, J.M.O., Nagashima, K., Hu, W.S., and Pathak,
1006 V.K. (2020). HIV-1 uncoats in the nucleus near sites of integration. *Proceedings of the*
1007 *National Academy of Sciences of the United States of America* *117*, 5486-5493.
- 1008 Campbell, E.M., and Hope, T.J. (2015). HIV-1 capsid: the multifaceted key player in HIV-1
1009 infection. *Nature reviews Microbiology* *13*, 471-483.
- 1010 Campbell, E.M., Perez, O., Anderson, J.L., and Hope, T.J. (2008). Visualization of a
1011 proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha. *The*
1012 *Journal of cell biology* *180*, 549-561.
- 1013 Carlson, L.A., Briggs, J.A., Glass, B., Riches, J.D., Simon, M.N., Johnson, M.C., Muller, B.,
1014 Grunewald, K., and Krausslich, H.G. (2008). Three-dimensional analysis of budding sites and
1015 released virus suggests a revised model for HIV-1 morphogenesis. *Cell host & microbe* *4*,
1016 592-599.
- 1017 Chandran, J.S., Sharp, P.S., Karyka, E., Aves-Cruzeiro, J., Coldicott, I., Castelli, L.,
1018 Hautbergue, G., Collins, M.O., and Azzouz, M. (2017). Site Specific Modification of Adeno-
1019 Associated Virus Enables Both Fluorescent Imaging of Viral Particles and Characterization of
1020 the Capsid Interactome. *Scientific reports* *7*, 14766.
- 1021 Cohen, S., and Arbely, E. (2016). Single-Plasmid-Based System for Efficient Noncanonical
1022 Amino Acid Mutagenesis in Cultured Mammalian Cells. *Chembiochem : a European journal*
1023 *of chemical biology* *17*, 1008-1011.

1024 de Chaumont, F., Dallongeville, S., Chenouard, N., Herve, N., Pop, S., Provoost, T., Meas-
1025 Yedid, V., Pankajakshan, P., Lecomte, T., Le Montagner, Y., *et al.* (2012). Icy: an open
1026 bioimage informatics platform for extended reproducible research. *Nature methods* *9*, 690-
1027 696.

1028 Dharan, A., Bachmann, N., Talley, S., Zwickelmaier, V., and Campbell, E.M. (2020). Nuclear
1029 pore blockade reveals that HIV-1 completes reverse transcription and uncoating in the
1030 nucleus. *Nature microbiology* *5*, 1088-1095.

1031 Engelman, A.N. (2021). HIV Capsid and Integration Targeting. *Viruses* *13*.

1032 Feiner, R.C., Teschner, J., Teschner, K.E., Radukic, M.T., Baumann, T., Hagen, S.,
1033 Hannappel, Y., Biere, N., Anselmetti, D., Arndt, K.M., *et al.* (2019). rAAV Engineering for
1034 Capsid-Protein Enzyme Insertions and Mosaicism Reveals Resilience to Mutational,
1035 Structural and Thermal Perturbations. *International journal of molecular sciences* *20*.

1036 Francis, A.C., Marin, M., Prellberg, M.J., Palermino-Rowland, K., and Melikyan, G.B.
1037 (2020a). HIV-1 Uncoating and Nuclear Import Precede the Completion of Reverse
1038 Transcription in Cell Lines and in Primary Macrophages. *Viruses* *12*.

1039 Francis, A.C., Marin, M., Shi, J., Aiken, C., and Melikyan, G.B. (2016). Time-Resolved
1040 Imaging of Single HIV-1 Uncoating In Vitro and in Living Cells. *PLoS pathogens* *12*,
1041 e1005709.

1042 Francis, A.C., Marin, M., Singh, P.K., Achuthan, V., Prellberg, M.J., Palermino-Rowland, K.,
1043 Lan, S., Tedbury, P.R., Sarafianos, S.G., Engelman, A.N., *et al.* (2020b). HIV-1 replication
1044 complexes accumulate in nuclear speckles and integrate into speckle-associated genomic
1045 domains. *Nature communications* *11*, 3505.

1046 Francis, A.C., and Melikyan, G.B. (2018). Single HIV-1 Imaging Reveals Progression of
1047 Infection through CA-Dependent Steps of Docking at the Nuclear Pore, Uncoating, and
1048 Nuclear Transport. *Cell host & microbe* *23*, 536-548 e536.

1049 Guedan, A., Caroe, E.R., Barr, G.C.R., and Bishop, K.N. (2021). The Role of Capsid in HIV-
1050 1 Nuclear Entry. *Viruses* *13*.

1051 Hulme, A.E., Kelley, Z., Foley, D., and Hope, T.J. (2015). Complementary Assays Reveal a
1052 Low Level of CA Associated with Viral Complexes in the Nuclei of HIV-1-Infected Cells.
1053 *Journal of virology* *89*, 5350-5361.

1054 Hulme, A.E., Perez, O., and Hope, T.J. (2011). Complementary assays reveal a relationship
1055 between HIV-1 uncoating and reverse transcription. *Proceedings of the National Academy of*
1056 *Sciences of the United States of America* *108*, 9975-9980.

1057 James, L.C. (2019). The HIV-1 Capsid: More than Just a Delivery Package. *Advances in*
1058 *experimental medicine and biology* *1215*, 69-83.

1059 Kane, M., Rebenburg, S.V., Takata, M.A., Zang, T.M., Yamashita, M., Kvaratskhelia, M.,
1060 and Bieniasz, P.D. (2018). Nuclear pore heterogeneity influences HIV-1 infection and the
1061 antiviral activity of MX2. *eLife* *7*.

1062 Kelemen, R.E., Erickson, S.B., and Chatterjee, A. (2018). Production and Chemoselective
1063 Modification of Adeno-Associated Virus Site-Specifically Incorporating an Unnatural Amino
1064 Acid Residue into Its Capsid. *Methods in molecular biology* *1728*, 313-326.

1065 Knockenhauer, K.E., and Schwartz, T.U. (2016). The Nuclear Pore Complex as a Flexible and
1066 Dynamic Gate. *Cell* *164*, 1162-1171.

1067 Kremer, J.R., Mastrorade, D.N., and McIntosh, J.R. (1996). Computer visualization of three-
1068 dimensional image data using IMOD. *Journal of structural biology* *116*, 71-76.

1069 Kukulski, W., Schorb, M., Welsch, S., Picco, A., Kaksonen, M., and Briggs, J.A. (2011).
1070 Correlated fluorescence and 3D electron microscopy with high sensitivity and spatial
1071 precision. *The Journal of cell biology* *192*, 111-119.

1072 Lang, K., and Chin, J.W. (2014). Cellular incorporation of unnatural amino acids and
1073 bioorthogonal labeling of proteins. *Chemical reviews* *114*, 4764-4806.

- 1074 Lanman, J., Lam, T.T., Emmett, M.R., Marshall, A.G., Sakalian, M., and Prevelige, P.E., Jr.
1075 (2004). Key interactions in HIV-1 maturation identified by hydrogen-deuterium exchange.
1076 *Nature structural & molecular biology* *11*, 676-677.
- 1077 Li, C., Burdick, R.C., Nagashima, K., Hu, W.S., and Pathak, V.K. (2021). HIV-1 cores retain
1078 their integrity until minutes before uncoating in the nucleus. *Proceedings of the National*
1079 *Academy of Sciences of the United States of America* *118*.
- 1080 Lukinavicius, G., Umezawa, K., Olivier, N., Honigsmann, A., Yang, G., Plass, T., Mueller, V.,
1081 Reymond, L., Correa, I.R., Jr., Luo, Z.G., *et al.* (2013). A near-infrared fluorophore for live-
1082 cell super-resolution microscopy of cellular proteins. *Nature chemistry* *5*, 132-139.
- 1083 Mamede, J.I., Cianci, G.C., Anderson, M.R., and Hope, T.J. (2017). Early cytoplasmic
1084 uncoating is associated with infectivity of HIV-1. *Proceedings of the National Academy of*
1085 *Sciences of the United States of America* *114*, E7169-E7178.
- 1086 Marquez, C.L., Lau, D., Walsh, J., Faysal, K.M.R., Parker, M.W., Turville, S.G., and
1087 Bocking, T. (2019). Fluorescence Microscopy Assay to Measure HIV-1 Capsid Uncoating
1088 Kinetics in vitro. *Bio-protocol* *9*, e3297.
- 1089 Mattei, S., Schur, F.K., and Briggs, J.A. (2016). Retrovirus maturation-an extraordinary
1090 structural transformation. *Current opinion in virology* *18*, 27-35.
- 1091 Melikyan, G.B., Markosyan, R.M., Hemmati, H., Delmedico, M.K., Lambert, D.M., and
1092 Cohen, F.S. (2000). Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the
1093 bundle configuration, induces membrane fusion. *The Journal of cell biology* *151*, 413-423.
- 1094 Muller, B., Tessmer, U., Schubert, U., and Krausslich, H.G. (2000). Human
1095 immunodeficiency virus type 1 Vpr protein is incorporated into the virion in significantly
1096 smaller amounts than gag and is phosphorylated in infected cells. *Journal of virology* *74*,
1097 9727-9731.
- 1098 Muller, T.G., Sakin, V., and Muller, B. (2019). A Spotlight on Viruses-Application of Click
1099 Chemistry to Visualize Virus-Cell Interactions. *Molecules* *24*.
- 1100 Muller, T.G., Zila, V., Peters, K., Schifferdecker, S., Stanic, M., Lucic, B., Laketa, V., Lusic,
1101 M., Muller, B., and Krausslich, H.G. (2021). HIV-1 uncoating by release of viral cDNA from
1102 capsid-like structures in the nucleus of infected cells. *eLife* *10*.
- 1103 Naghavi, M.H. (2021). HIV-1 capsid exploitation of the host microtubule cytoskeleton during
1104 early infection. *Retrovirology* *18*, 19.
- 1105 Nikic, I., Estrada Girona, G., Kang, J.H., Paci, G., Mikhaleva, S., Koehler, C., Shymanska,
1106 N.V., Ventura Santos, C., Spitz, D., and Lemke, E.A. (2016). Debugging Eukaryotic Genetic
1107 Code Expansion for Site-Specific Click-PAINT Super-Resolution Microscopy. *Angewandte*
1108 *Chemie* *55*, 16172-16176.
- 1109 Nikic, I., and Lemke, E.A. (2015). Genetic code expansion enabled site-specific dual-color
1110 protein labeling: superresolution microscopy and beyond. *Current opinion in chemical*
1111 *biology* *28*, 164-173.
- 1112 Novikova, M., Zhang, Y., Freed, E.O., and Peng, K. (2019). Multiple Roles of HIV-1 Capsid
1113 during the Virus Replication Cycle. *Virologica Sinica* *34*, 119-134.
- 1114 Pear, W.S., Nolan, G.P., Scott, M.L., and Baltimore, D. (1993). Production of high-titer
1115 helper-free retroviruses by transient transfection. *Proceedings of the National Academy of*
1116 *Sciences of the United States of America* *90*, 8392-8396.
- 1117 Peng, K., Muranyi, W., Glass, B., Laketa, V., Yant, S.R., Tsai, L., Cihlar, T., Muller, B., and
1118 Krausslich, H.G. (2014). Quantitative microscopy of functional HIV post-entry complexes
1119 reveals association of replication with the viral capsid. *eLife* *3*.
- 1120 Pereira, C.F., Ellenberg, P.C., Jones, K.L., Fernandez, T.L., Smyth, R.P., Hawkes, D.J.,
1121 Hijnen, M., Vivet-Boudou, V., Marquet, R., Johnson, I., *et al.* (2011). Labeling of multiple
1122 HIV-1 proteins with the biarsenical-tetracysteine system. *PloS one* *6*, e17016.

- 1123 Pizzato, M., Erlwein, O., Bonsall, D., Kaye, S., Muir, D., and McClure, M.O. (2009). A one-
1124 step SYBR Green I-based product-enhanced reverse transcriptase assay for the quantitation of
1125 retroviruses in cell culture supernatants. *Journal of virological methods* *156*, 1-7.
- 1126 Price, A.J., Jacques, D.A., McEwan, W.A., Fletcher, A.J., Essig, S., Chin, J.W., Halambage,
1127 U.D., Aiken, C., and James, L.C. (2014). Host cofactors and pharmacologic ligands share an
1128 essential interface in HIV-1 capsid that is lost upon disassembly. *PLoS pathogens* *10*,
1129 e1004459.
- 1130 Rankovic, S., Ramalho, R., Aiken, C., and Rousso, I. (2018). PF74 Reinforces the HIV-1
1131 Capsid To Impair Reverse Transcription-Induced Uncoating. *Journal of virology* *92*.
- 1132 Rensen, E., Mueller, F., Scoca, V., Parmar, J.J., Souque, P., Zimmer, C., and Di Nunzio, F.
1133 (2021). Clustering and reverse transcription of HIV-1 genomes in nuclear niches of
1134 macrophages. *The EMBO journal* *40*, e105247.
- 1135 Rihn, S.J., Wilson, S.J., Loman, N.J., Alim, M., Bakker, S.E., Bhella, D., Gifford, R.J., Rixon,
1136 F.J., and Bieniasz, P.D. (2013). Extreme genetic fragility of the HIV-1 capsid. *PLoS*
1137 *pathogens* *9*, e1003461.
- 1138 Saito, A., and Yamashita, M. (2021). HIV-1 capsid variability: viral exploitation and evasion
1139 of capsid-binding molecules. *Retrovirology* *18*, 32.
- 1140 Sakin, V., Hanne, J., Dunder, J., Anders-Osswein, M., Laketa, V., Nikic, I., Krausslich, H.G.,
1141 Lemke, E.A., and Muller, B. (2017). A Versatile Tool for Live-Cell Imaging and Super-
1142 Resolution Nanoscopy Studies of HIV-1 Env Distribution and Mobility. *Cell chemical*
1143 *biology* *24*, 635-645 e635.
- 1144 Schaller, T., Ocwieja, K.E., Rasaiyaah, J., Price, A.J., Brady, T.L., Roth, S.L., Hue, S.,
1145 Fletcher, A.J., Lee, K., KewalRamani, V.N., *et al.* (2011). HIV-1 capsid-cyclophilin
1146 interactions determine nuclear import pathway, integration targeting and replication
1147 efficiency. *PLoS pathogens* *7*, e1002439.
- 1148 Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T.,
1149 Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., *et al.* (2012). Fiji: an open-source platform
1150 for biological-image analysis. *Nature methods* *9*, 676-682.
- 1151 Schmied, W.H., Elsasser, S.J., Uttamapinant, C., and Chin, J.W. (2014). Efficient multisite
1152 unnatural amino acid incorporation in mammalian cells via optimized pyrrolysyl tRNA
1153 synthetase/tRNA expression and engineered eRF1. *Journal of the American Chemical Society*
1154 *136*, 15577-15583.
- 1155 Schorb, M., Gaechter, L., Avinoam, O., Sieckmann, F., Clarke, M., Bebeacua, C., Bykov,
1156 Y.S., Sonnen, A.F., Lihl, R., and Briggs, J.A.G. (2017). New hardware and workflows for
1157 semi-automated correlative cryo-fluorescence and cryo-electron microscopy/tomography.
1158 *Journal of structural biology* *197*, 83-93.
- 1159 Selyutina, A., Persaud, M., Lee, K., KewalRamani, V., and Diaz-Griffero, F. (2020). Nuclear
1160 Import of the HIV-1 Core Precedes Reverse Transcription and Uncoating. *Cell reports* *32*,
1161 108201.
- 1162 Shi, J., Zhou, J., Shah, V.B., Aiken, C., and Whitby, K. (2011). Small-molecule inhibition of
1163 human immunodeficiency virus type 1 infection by virus capsid destabilization. *Journal of*
1164 *virology* *85*, 542-549.
- 1165 Si, L., Xu, H., Zhou, X., Zhang, Z., Tian, Z., Wang, Y., Wu, Y., Zhang, B., Niu, Z., Zhang,
1166 C., *et al.* (2016). Generation of influenza A viruses as live but replication-incompetent virus
1167 vaccines. *Science* *354*, 1170-1173.
- 1168 Thenin-Houssier, S., and Valente, S.T. (2016). HIV-1 Capsid Inhibitors as Antiretroviral
1169 Agents. *Current HIV research* *14*, 270-282.
- 1170 Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt,
1171 J.A., and Muller, O.J. (2012). Novel random peptide libraries displayed on AAV serotype 9
1172 for selection of endothelial cell-directed gene transfer vectors. *Gene therapy* *19*, 800-809.

- 1173 von Schwedler, U.K., Stray, K.M., Garrus, J.E., and Sundquist, W.I. (2003). Functional
1174 surfaces of the human immunodeficiency virus type 1 capsid protein. *Journal of virology* *77*,
1175 5439-5450.
- 1176 Wang, L., Frei, M.S., Salim, A., and Johnsson, K. (2019). Small-Molecule Fluorescent Probes
1177 for Live-Cell Super-Resolution Microscopy. *Journal of the American Chemical Society* *141*,
1178 2770-2781.
- 1179 Wei, X., Decker, J.M., Liu, H., Zhang, Z., Arani, R.B., Kilby, J.M., Saag, M.S., Wu, X.,
1180 Shaw, G.M., and Kappes, J.C. (2002). Emergence of resistant human immunodeficiency virus
1181 type 1 in patients receiving fusion inhibitor (T-20) monotherapy. *Antimicrobial agents and*
1182 *chemotherapy* *46*, 1896-1905.
- 1183 Weigel, P.H., and Oka, J.A. (1981). Temperature dependence of endocytosis mediated by the
1184 asialoglycoprotein receptor in isolated rat hepatocytes. Evidence for two potentially rate-
1185 limiting steps. *The Journal of biological chemistry* *256*, 2615-2617.
- 1186 Xu, H., Franks, T., Gibson, G., Huber, K., Rahm, N., Strambio De Castillia, C., Luban, J.,
1187 Aiken, C., Watkins, S., Sluis-Cremer, N., *et al.* (2013). Evidence for biphasic uncoating
1188 during HIV-1 infection from a novel imaging assay. *Retrovirology* *10*, 70.
- 1189 Yuan, Z., Wang, N., Kang, G., Niu, W., Li, Q., and Guo, J. (2017). Controlling Multicycle
1190 Replication of Live-Attenuated HIV-1 Using an Unnatural Genetic Switch. *ACS synthetic*
1191 *biology* *6*, 721-731.
- 1192 Zhang, C., Zhou, X., Yao, T., Tian, Z., and Zhou, D. (2018). Precision Fluorescent Labeling
1193 of an Adeno-Associated Virus Vector to Monitor the Viral Infection Pathway. *Biotechnology*
1194 *journal* *13*, e1700374.
- 1195 Zila, V., Margiotta, E., Turonova, B., Muller, T.G., Zimmerli, C.E., Mattei, S., Allegretti, M.,
1196 Borner, K., Rada, J., Muller, B., *et al.* (2021). Cone-shaped HIV-1 capsids are transported
1197 through intact nuclear pores. *Cell* *184*, 1032-1046 e1018.
- 1198 Zila, V., Muller, T.G., Laketa, V., Muller, B., and Krausslich, H.G. (2019). Analysis of CA
1199 Content and CPSF6 Dependence of Early HIV-1 Replication Complexes in SupT1-R5 Cells.
1200 *mBio* *10*.
- 1201 Zurnic Bonisch, I., Dirix, L., Lemmens, V., Borrenberghs, D., De Wit, F., Vernailen, F.,
1202 Rocha, S., Christ, F., Hendrix, J., Hofkens, J., *et al.* (2020). Capsid-Labelled HIV To
1203 Investigate the Role of Capsid during Nuclear Import and Integration. *Journal of virology* *94*.
1204